Hosted on MSN8d
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
It was a busy week for the biotech sector, with regulatory and pipeline updates. Sage Therapeutics SAGE was in focus after it ...
SAGE Stock Up on Rejecting BIIB’s Proposal
Failed to fetch dynamically imported module: https://finance.yahoo.com/assets/_app/immutable/nodes/2.CBWletoF.js ...
Sage rejects Biogen’s buyout offer, but says it's open to deals
Sage Therapeutics has rejected the unsolicited acquisition offer it received earlier this month from longtime partner Biogen ...
The Pharma Letter9d
Sage rejects Biogen’s unsolicited bid, but open to other offers
Cambridge, USA-based biotech Sage Therapeutics yesterday announced that, while rejecting an unsolicited takeover offer, its ...
BioSpace6d
You Can’t Buy Us: Biotechs Turn to Courts to Fight Off Potential Buyers
Biogen’s effort to buy Sage against the board’s wishes and a long-time effort by investor Alcorn to scuttle Aurion’s IPO ...
BioSpace10d
Sage Rejects Biogen’s Unsolicited Offer, Will Seek Strategic Alternatives
Following a lawsuit filed last week, Sage has officially rejected Biogen’s unsolicited buyout offer, which valued the ...
Nasdaq21d
Biotech Stock Roundup: MRNA, NTLA Down on Updates, SAGE Up on Biogen's Offer & Other Updates
Sage Therapeutics SAGE announced that its partner ... Inc. GSK plc GSK announced an agreement to acquire clinical-stage private biotech IDRx, which makes precision therapeutics for treating ...
FiercePharma25d
Biogen, already a Sage partner and equity owner, offers to buy the rest of the neuro biotech
A yearslong partner of neuroscience player Sage, Biogen already owns 10.2% of the Cambridge, Massachusetts-based biotech, according to the filing. In its own press release, Sage called the ...
Trump’s push to freeze funding leaves researchers anxious about delayed scientific breakthroughs
Research photo from the National Cancer Institute, shared via Unsplash. (NCI Photo) When Luca Foschini, head of Seattle's ...
Nasdaq8d
Biotech Stock Roundup: SAGE Up on Declining BIIB's Offer, CYTK, AKRO Up on Updates
Sage Therapeutics stock gained after it announced that its board of directors has rejected the unsolicited, non-binding proposal offer from biotech giant Biogen to acquire the remaining shares of ...